136592-00-2

Basic information

• Product Name: Ethanone, 2-chloro-1-(6-chloro-3-pyridinyl)- (9CI)
• Synonyms: Ethanone, 2-chloro-1-(6-chloro-3-pyridinyl)- (9CI);2-chloro-1-(6-chloropyridin-3-yl)ethanone;2-chloro-1-(6-chloropyridin-3-yl)ethan-1-one
• CAS NO: 136592-00-2
• Molecular Formula: C₇H₅Cl₂NO
• Molecular Weight: 190.0267
• Product Categories: ACETYLHALIDE
• Mol File: 136592-00-2.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 328.8±27.0 °C(Predicted)
• Appearance: /
• Density: 1.381±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -2.57±0.10(Predicted)
• CAS DataBase Reference: Ethanone, 2-chloro-1-(6-chloro-3-pyridinyl)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 2-chloro-1-(6-chloro-3-pyridinyl)- (9CI)(136592-00-2)
• EPA Substance Registry System: Ethanone, 2-chloro-1-(6-chloro-3-pyridinyl)- (9CI)(136592-00-2)

Safety Data

• Hazardous Substances Data: 136592-00-2(Hazardous Substances Data)

Upstream product

• 186581-53-3 diazomethane 
• 5326-23-8 6-Chloro-3-pyridinecarboxylic acid 
• 53939-30-3 5-bromo-2-chloropyridine 
• 67442-07-3 2-chloro-N-methoxy-N-methylacetamide 
• 58757-38-3 6-Chloronicotinoyl chloride 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 79-37-8 oxalyl dichloride 

Downstream Products

• 1251957-87-5 2-[4-(2-{[(2R)-2-hydroxy-2-(pyridin-3-yl)ethyl]amino}-2-methylpropyl)phenyl]-N-(5-methylisoxazol-3-yl)acetamide 
• 1251957-86-4 2-[4-(2-{[(2R)-2-(6-chloropyridin-3-yl)-2-hydroxyethyl]amino}-2-methylpropyl)phenyl]-N-(5-methylisoxazol-3-yl)acetamide 

Relevant articles and documents

ANTIVIRAL COMPOUNDS

The present invention provides compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HETEROCYCLIC AMINE DERIVATIVES

The present invention relates to compounds of formula (I) wherein R1 is hydrogen, lower alkyl, halogen, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen, cyano, nitro, C3-6-cycloalkyl, -CH2-C3-6-cycloalkyl, -O-CH2-C3-6-cycloalkyl, -O-(CH2)2-O-lower alkyl, S(O)2CH3, SF5, -C(O)NH-lower alkyl, phenyl, -O-pyrimidinyl, optionally substituted by lower alkoxy substituted by halogen, or is benzyl, oxetanyl or furanyl; m Ar is aryl or heteroaryl, selected from the group consisting of phenyl, naphthyl, pyrimidinyl, pyridinyl, benzothiazolyl, quinolinyl, quinazolinyl, benzo[d][1.3]dioxolyl, 5,6,7,8- tetrahydro-quinazolinyl, pyrazolyl, pyrazinyl, pyridazinyl, or 1,3,4-oxadiazolyl; Y is a bond, -CH2-, -CH2CH2-, -CH(CF3)- or -CH(CH3)-; R2 is hydrogen or lower alkyl; A is CR or N; and R is hydrogen, cyano, halogen or lower alkyl; R' is hydrogen or halogen; with the proviso that when R' is halogen, then A is CH; B is CH or N; n is 0, 1 or 2; X is a bond, -CH2- or -O-; pharmaceutical active acid addition salts thereof. It has now been found that the compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

The chemistry of pseudomonic acid part 14. Synthesis and in vivo biological activity of heterocyclyl substituted oxazole derivatives

Semisynthetic analogues of pseudomonic acid A have been prepared containing a heterocyclyl substituted oxazole. Derivatives in which the heterocycle was thiophene, furan, pyridine, or isoxazole showed good antibacterial potency and were further evaluated in vivo. Both pharmacokinetic parameters and oral activity against an experimental intraperitoneal sepsis were superior to results obtained from previously described pseudomonic acid A derivatives.